Irbesartan/hydrochlorothiazide

Drug Profile

Irbesartan/hydrochlorothiazide

Alternative Names: Avalide; Avapro HCT; CoAprovel; Karvezide

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class Antihypertensives; Benzothiadiazines; Biphenyl compounds; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic nephropathies; Hypertension

Most Recent Events

  • 31 Mar 2015 Launched for Hypertension in Algeria, Morocco and Philippines (PO) before March 2015
  • 03 Oct 2012 Bristol-Myers Squibb intends to terminate its licence for irbesartan/hydrochlorothiazide in all countries, effective 1 January 2013
  • 04 Apr 2012 First generic version of irbesartan hydrochlorothiazide launched in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top